X0508 4 2026-01-23 0001438533 Travere Therapeutics, Inc. TVTX 0001763494 Dube Eric M C/O TRAVERE THERAPEUTICS, INC. 3611 VALLEY CENTRE DR., SUITE 300 SAN DIEGO CA 92130 true true false false CHIEF EXECUTIVE OFFICER 1 Common Stock 2026-01-23 4 M 0 8135 15.46 A 427308 D Common Stock 2026-01-23 4 S 0 8135 30.0127 D 419173 D Common Stock 2026-01-27 4 M 0 51865 15.46 A 471038 D Common Stock 2026-01-27 4 S 0 51865 30.097 D 419173 D Employee stock option (right to buy) 15.46 2026-01-23 4 M 0 8135 0 D 2030-01-31 Common Stock 8135 171865 D Employee stock option (right to buy) 15.46 2026-01-27 4 M 0 51865 0 D 2030-01-31 Common Stock 51865 120000 D This sale was made pursuant to a written plan adopted on June 16, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended. The weighted average sale price for the transaction reported was $30.0127, and the range of prices were between $30.00 and $30.13. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The weighted average sale price for the transaction reported was $30.097, and the range of prices were between $30.00 and $30.49. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each price will be provided. The stock option is fully vested and exercisable. /s/ Elizabeth E. Reed, Attorney-in-Fact 2026-01-27